SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
康康
Lv1
30 积分
2023-05-10 加入
最近求助
最近应助
互助留言
Systemic Light Chain Amyloidosis
2天前
已关闭
Systemic Light Chain Amyloidosis
2天前
已关闭
Zevorcabtagene Autoleucel: First Approval
22天前
已完结
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
22天前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
25天前
已完结
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma
2个月前
已完结
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
2个月前
已完结
Daratumumab maintenance in patients with myeloma
2个月前
已完结
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
2个月前
已完结
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy
3个月前
已完结
没有进行任何应助
找到了【积分已退回】
1年前
您好能下到附件吗
1年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论